Arrhythmias & electrophysiology
Leadless atrial versus transvenous pacing for sinus node dysfunction: 1-year outcomes from the leadless ARRIVE real-world study
Authors' conclusion
AVEIR AR was associated with fewer long-term complications and reinterventions compared with DCTV and RATV, while 1-year mortality remained similar.
Study context
- Population
- Medicare patients with de novo AVEIR AR leadless pacemakers (LP) or transvenous (TV) pacemaker implantation, January 2024 to March 2025
- Participants
- 428 / 39,881 / 389
- Exposure
- AVEIR AR leadless atrial pacemaker vs dual-chamber or right-atrial transvenous pacemakers
- AVEIR ARn = 428
- DCTVn = 39,881reference
- RATVn = 389reference
- Outcome
- 30-day complications and 1-year outcomes (complications, device-reinterventions, all-cause mortality)
- Follow-up
- 30 days and 1 year
Methodological detailspropensity score overlap weighting, Medicare fee-for-service claims
- Propensity score overlap weighting
- Medicare fee-for-service claims
Main finding
As reported in the abstract
Complications
AVEIR AR
- 30-day complications vs DCTV (adjusted)
- 6.7%
- 30-day complications vs RATV
- 6.9%
- 1-year complications vs DCTV
- 3.6%
- 1-year complications vs RATV
- 3.3%
DCTV
- 30-day complications (adjusted)
- 9.4%
- 1-year complications
- 8.5%
RATV
- 30-day complications
- 6.7%
- 1-year complications
- 7.5%
30-day complications vs DCTV (adjusted)
AVEIR AR6.7%
DCTVNot reported in the abstract
RATVNot reported in the abstract
30-day complications vs RATV
AVEIR AR6.9%
DCTVNot reported in the abstract
RATVNot reported in the abstract
1-year complications vs DCTV
AVEIR AR3.6%
DCTVNot reported in the abstract
RATVNot reported in the abstract
1-year complications vs RATV
AVEIR AR3.3%
DCTVNot reported in the abstract
RATVNot reported in the abstract
30-day complications (adjusted)
AVEIR ARNot reported in the abstract
DCTV9.4%
RATVNot reported in the abstract
1-year complications
AVEIR ARNot reported in the abstract
DCTV8.5%
RATV7.5%
30-day complications
AVEIR ARNot reported in the abstract
DCTVNot reported in the abstract
RATV6.7%
- AVEIR AR vs DCTV · 30-day complications
- OR 0.7
- AVEIR AR vs DCTV · 1-year complications
- HR 0.4
- AVEIR AR vs RATV · 1-year complications
- HR 0.4
Observational data: associations, not effects.
Further findings
Device-related complications and reinterventions · 1 year
- Device-related complications reduced vs DCTV
- Reinterventions reduced vs both DCTV and RATV
All-cause mortality · 1 year
- Mortality comparable across all groups
Original publication
Leadless atrial versus transvenous pacing for sinus node dysfunction: 1-year outcomes from the leadless ARRIVE real-world study. Europace. Published 14 April 2026. doi:10.
Summarised from the published abstract; every number is checked against it